Search | Clinical Trials Finder

Conditions: Healthy Participants
Interventions: ASP8731, ASP8731 Matching Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Dementia With Lewy Bodies (DLB)
Interventions: Neflamapimod; Drug
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 55 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 22
States / cities: La Jolla, California • Santa Monica, California • Aurora, Colorado + 18 more

Conditions: Insomnia Disorder
Interventions: Daridorexant 25 mg, Daridorexant 50 mg, Placebo; Drug · Other
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 930 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 36
States / cities: Anniston, Alabama • Birmingham, Alabama • Little Rock, Arkansas + 33 more

Conditions: Microbial Composition, Immune Function
Interventions: Probiotic Capsule, Placebo; Drug
Lead sponsor: Sheffield Hallam University; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Adults
Interventions: RSB11-HI Heat-Inactivated Postbiotic, Placebo; Dietary Supplement · Other
Lead sponsor: Able Biolabs, LLC; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity & Overweight
Interventions: CX11, Placebo; Drug · Other
Lead sponsor: Corxel Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate, montelukast, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 50
States / cities: Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Dapagliflozin, Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 20
States / cities: Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CNM-Au8, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Elderly, Parkinson Disease
Interventions: IkT-148009, Placebo; Drug
Lead sponsor: ABLi Therapeutics, Inc.; Industry
Eligibility: 55 Years to 70 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Long Beach, California • Hallandale, Florida • Farmington Hills, Michigan + 1 more

Conditions: Healthy
Interventions: PF-07328948, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Gedeon Richter Plc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Culver City, California • Atlanta, Georgia • Bloomfield Hills, Michigan + 5 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 87
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 77 more

Conditions: Healthy
Interventions: 0.5mg AZ-010, 1mg AZ-010, 3mg AZ-010; Combination Product
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Coronary Heart Disease
Interventions: DFV890, DFV890 Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Northridge, California • Boca Raton, Florida • Jacksonville, Florida + 3 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Lenvatinib, Lenvatinib matched placebo, BSC; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Casa Grande, Arizona • Tucson, Arizona • Gilroy, California + 8 more

Conditions: Fractures
Interventions: Teriparatide, Placebo; Drug
Lead sponsor: Ohio Orthopedic Center of Excellence; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Upper Arlington, Ohio

Conditions: Liver Cirrhosis, Biliary
Interventions: Placebo, Obeticholic Acid (OCA); Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 4
States / cities: Detroit, Michigan • Houston, Texas • Richmond, Virginia + 1 more

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Osteoporosis (Senile)
Interventions: doxercalciferol capsules, Hectorol®, Matched Placebo (Capsules); Drug
Lead sponsor: Creighton University; Other
Eligibility: 60 Years to 78 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 1994
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV Infection
Interventions: Recombinant Lactoferrin, Placebo; Drug
Lead sponsor: Jason Baker; Other
Eligibility: 40 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
Interventions: Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Pine Bluff, Arkansas • Chula Vista, California • El Centro, California + 16 more

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Search by objective public record fields.

A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Gut Microbiome Response to Long-Haul Travel in Elite Football Players

Evaluation of RSB11-HI Postbiotic Supplementation for Supporting Weight Management, Metabolic Wellness, and Quality of Life in Healthy Adults

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

HEALEY ALS Platform Trial - Regimen C CNM-Au8

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Staccato® Granisetron Multiple Dose PK

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

To Study the Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women in a Long Term 2 Year Study

Lactoferrin Treatment in HIV Patients

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants